Skip header and navigation

51 records – page 1 of 6.

Document Type
Evidence Search Report
Review Code
EOC072102-01 ESR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC072102-01 ESR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Category
Epidemiology
Subject
Pediatrics
Natural History
Symptoms
Transmission
Population
All Pediatrics
Priority Level
Level 5 completed within 2 weeks
Cite As
Dalidowicz, M; Howell-Spooner, B; Ellsworth, C. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 31; Document no.: EOC072102-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 44 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC072102 RR
Question Submitted
July 27, 2020
Date Completed
July 31, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Children and adolescents (0 to 18 years) contributed 1- 10% of laboratory confirmed cases of COVID-19 globally. · Children have been reported to have milder symptoms of COVID-19 and have shown better prognosis as compared to adults. · Severe cases presenting as a multisystem inflammatory syndrome in children (MIS-C) has been reported in some pediatric cases of COVID-19. Many of these children meet the criteria for complete or incomplete Kawasaki disease, but different clinical presentations of this inflammatory disorder are being reported. · Underlying medical conditions and comorbidities such as such as sickle cell disease, immunocompromised condition, obesity, cancer, cardiovascular disease, and asthma have been associated with severity and complications from COVID-19 infection in pediatric patients. · Although rare, death from COVID-19 in children have been reported, with a case fatality rate of less than 0.5%.
Category
Epidemiology
Subject
Pediatrics
Natural History
Symptoms
Transmission
Population
All Pediatrics
Priority Level
Level 5 completed within 2 weeks
Cite As
Asamoah, G; Muhajarine, N; Dalidowicz, M; Ellsworth, C; Howell-Spooner, B. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 27; Document no.: EOC072102 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 17 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF123001-01 ESR
Question Submitted
December 30, 2020
Date Completed
December 31, 2020
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Evidence Search Report
Review Code
INF123001-01 ESR
Question Submitted
December 30, 2020
Date Completed
December 31, 2020
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Subject
Variants
Population
All
Clinical Setting
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Howell-Spooner, B; Miller, L. What is the R0 (basic reproduction number) of the new coronavirus variant detected in the UK? 2020 Dec 31; Document no.: INF123001-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 8 p. (CEST evidence search report)
Review History
INF123001 RR: January 4, 2021
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC040101-01 ESR
Question Submitted
April 1, 2020
Date Completed
April 1, 2020
Status
3. Completed
Research Team
EOC
Document Type
Evidence Search Report
Review Code
EOC040101-01 ESR
Question Submitted
April 1, 2020
Date Completed
April 1, 2020
Status
3. Completed
Research Team
EOC
Category
Epidemiology
Infection Prevention and Control
Subject
Aerosols
Risk
Transmission
Population
All
Clinical Setting
Ambulatory
Priority Level
Level 2 completed within 8 hours
Cite As
Dalidowicz, M; Young, C. What is the degree of COVID-19 transmission through the administration of nebulizer medication either in clinical practice or in animal experiments? 2020 Apr 1; Document no.: EOC040101-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB042201-01 ESR
Question Submitted
April 22, 2020
Date Completed
23-Apr-2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB042201-01 ESR
Question Submitted
April 22, 2020
Date Completed
23-Apr-2020
Status
3. Completed
Research Team
Laboratory
Category
Diagnostics
Epidemiology
Subject
Testing
Public Health
Population
All
Clinical Setting
Community
Priority Level
Level 3 completed within 2-3 days
Cite As
Duncan, V. What sampling method is most appropriate for population testing? 2020 Apr 23; Document no.: LAB042201-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 14 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB042202-01 ESR
Question Submitted
April 22, 2020
Date Completed
23-Apr-2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB042202-01 ESR
Question Submitted
April 22, 2020
Date Completed
23-Apr-2020
Status
3. Completed
Research Team
Laboratory
Category
Diagnostics
Epidemiology
Subject
Testing
Public Health
Population
All
Clinical Setting
Community
Priority Level
Level 3 completed within 2-3 days
Cite As
Howell-Spooner, B. What frequency of repeat population screening will be required? 2020 Apr 23; Document no.: LAB042202-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 40 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF042401-01 ESR
Question Submitted
24-Apr-2020
Date Completed
25-Apr-2020
Status
3. Completed
Research Team
Infectious Disease
Document Type
Evidence Search Report
Review Code
INF042401-01 ESR
Question Submitted
24-Apr-2020
Date Completed
25-Apr-2020
Status
3. Completed
Research Team
Infectious Disease
Category
Infection Prevention and Control
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Natural History
Asymptomatic
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS-CoV-2? 2020 Apr 25; Document no.: INF042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
INF042401 RR
Question Submitted
24-Apr-2020
Date Completed
April 27, 2020
Status
3. Completed
Research Team
Infectious Disease
Document Type
Rapid Review
Review Code
INF042401 RR
Question Submitted
24-Apr-2020
Date Completed
April 27, 2020
Status
3. Completed
Research Team
Infectious Disease
Key Findings
The period of communicability of symptomatic SARS CoV-2 infections remains unclear.
Viral RNA shedding measured from the onset of illness is a common proxy used to estimate the period of communicability; however, confirmation of the viability of viral remnants in secretions through culture or other methods seldom occurs in practice.
Several factors including age, male sex and clinical severity influence individual variation in viral shedding and suggest the need for tailored control efforts.
Temporal patterns in viral shedding across different types of bodily secretions has implications for transmissibility and criteria for discontinuation of control measures during convalescence.
Category
Infection Prevention and Control
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Natural History
Asymptomatic
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Williams-Roberts, H; Lee, S; Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS CoV-2? 2020 Apr 27; Document no.: INF042401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
PH042401-01 ESR
Question Submitted
24-Apr-2020
Date Completed
April 27, 2020
Status
3. Completed
Research Team
Public Health
Document Type
Evidence Search Report
Review Code
PH042401-01 ESR
Question Submitted
24-Apr-2020
Date Completed
April 27, 2020
Status
3. Completed
Research Team
Public Health
Category
Diagnostics
Epidemiology
Subject
Screening
Population
All
Neonates
Infants
All Pediatrics
Clinical Setting
Ambulatory
Emergency
Long Term Care
Other
OR
Priority Level
Level 4 completed within 1 week
Cite As
Dalidowicz, M; Mueller, M. What is the sensitivity and specificity of screening checklists and temperature checks for detecting the presence of COVID-19 in individuals? 2020 Apr 27; Document no.: PH042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB042201 RR
Question Submitted
April 22, 2020
Date Completed
April 23, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB042201 RR
Question Submitted
April 22, 2020
Date Completed
April 23, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
For COVID-19 there are no published data to identify optimal population sampling methods, however, a population-based sample in which testing is performed for both rt-PCR and serology might be recommended. There are also opportunities to examine innovative sampling strategies being used in pilot studies underway in other jurisdictions.
Category
Diagnostics
Epidemiology
Subject
Testing
Public Health
Population
All
Clinical Setting
Community
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Reeder, B; Duncan, V. What sampling method is most appropriate for population testing? 2020 Apr 23; Document no.: LAB042201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail

51 records – page 1 of 6.